Chondromas And Their Impact On Bone Health

Get health & wellness advice into your inbox

Your privacy is important to us. Any information you provide to us via this website may be placed by us on servers. If you do not agree to these placements, please do not provide the information.

Best Milk Alternative


Bone health is very important, particularly during development, for mobility, protection of vital organs, providing space for bone marrow, and storage and supply of calcium. There are many pathological conditions that can alter the health and subsequently the structure of our bones.

Chondromas are rare, benign tumours of the hyaline cartilage, the soft, cushion-like tissue at the ends of bones where they meet to form joints.1 They are often found in the humerus (upper-arm bone), tibia (lower leg bone), and femur (thigh bone) as well as short bones in hands and feet. They are composed of only cartilage cells, namely chondrocytes, and matrix. Normally, they are isolated and have a slow, monotonous growth pattern.2 Though the cause for chondromas is not known, they are thought to occur due to either overgrowth of cartilage or continuing growth of the embryonic cartilage. Unfortunately, chondromas can occasionally inhibit bone growth in the affected area and potentially lead to skeletal deformities, or bone fractures. In some cases, chondromas can undergo malignant transformation into chondrosarcoma.

Types of chondromas

Chondromas can be classified as:

  • Enchondromas originate from the hollow section of the bone called medullary cavity.
  • Periosteal chondromas originate from the dense outer layer of bone called the cortex.
  • Soft tissue chondromas (STCs), originate in soft tissues and not bones.


In humans, mature bones are formed when the tissue at the ends of long bones, called the growth plate, closes after puberty (between ages 16-18), halting the growth and development of long bones.3 Enchondromas are likely to develop due to mutation and the subsequent overactivation of the receptor that delays terminal-stage differentiation of proliferating chondrocytes.4 In patients with Maffucci syndrome and Ollier syndrome, both of which are characterised by multiple enchondromas, the malignant transformation of enchondroma into chondrosarcoma is as high as 50%.5 Epidemiologically, enchondroma is the 2nd most common benign cartilage lesion affecting 3% of the population, with the most common regions being the hands (60% of all cases) and femur (accounting for 20% of all cases).6 

Periosteal and soft tissue chondromas

Whilst sharing some basic pathological features as enchondromas, periosteal chondromas and soft tissue chondromas are rare benign chondromas present in different regions. Periosteal chondromas occur on the periosteal surface of long and short tubular bones. STCs commonly occur in soft tissues on the hands and feet, often with no relation to the underlying bone, either tendon or tendon sheaths.7 They do not invade surrounding bone. Usually, STCs are round, slow-growing masses made of hyaline cartilage, rarely exceeding 3cm in diameter.8 Only 1.5% of all chondroma cases worldwide are associated with STCs, with most cases (over 95%) occurring in the hands and feet, commonly between the ages of 30-60.9,10 STCs are commonly painless unless they exert pressure onto weight-bearing surface or surrounding structures. So far, no cases of STC malignant transformation have been reported.8,9 Periosteal chondromas account for 2% of all chondroma cases worldwide, occurring mostly in people assigned male at birth below the age of 30.11,12,13 They are slow-growing tumours (smaller than 3cm) commonly present in the humerus, femur and tibia.12,14 A tissue diameter beyond 3cm is associated with periosteal chondrosarcoma, which would continue growing even after bone maturity.15 Patients with periosteal chondroma present signs of swelling and aching pain, whilst some can feel the tumour mass.

Impact of chondromas on bone health

Chondromas have differing impacts on bone health depending on their location and size. 

Localised effects on bone

Skeletal abnormalities, unequal limb lengths, and a possible risk of developing chondrosarcoma are just a few of the clinical issues brought on by enchondromas. As previously mentioned, there are 2 clinical disorders associated with the presence of multiple enchondromas, namely Ollier and Maffucci disease, both of which are characterised by the asymmetrically distributed cartilage lesions.16. In patients with periosteal chondromas, the chondroma is localised to the bone because it is possible that the tumour will erode the underlying bone resulting in a dip of the bone (saucer-shaped depression). On the side of the tumour that faces the bone, sclerosis forms.17 

Systemic effects on bone health

STCs are extra-skeletal, often showing no association with the bone. However, patients with STCs tend to develop non-bone related disorders, often in the tendon, from where they originate, or the surrounding tissues. Generally, STCs are painless, unless they collide with the surrounding structures. Trigger finger is a disorder affecting one or more tendons in the hand making it difficult to bend the thumb and fingers. In rare cases, STCs clinically manifest into trigger finger.18

Management and treatment of chondromas

Monitoring and observation

Typically, enchondromas and periosteal chondromas do not cause pain, and patients are often asymptomatic. So, they are often diagnosed incidentally by X-rays. Enchondromas appear as small, darkened tumours in the centre of the bone, often containing white spots (of calcification). Periosteal chondromas present on the outside border of the bone and show up as soft tissue. However, STCs do not always show up on X-ray scans because they do not calcify. CT or MRI scans can also be used to diagnose and monitor patients. To diagnose enchondromas, bone scans can also be ordered, where a small dose of radioactive dye is injected which is only taken up by benign and malignant tumours. Alternatively, biopsies could be done on chondromas if the imaging tests are inconclusive. Unfortunately, in the case of enchondroma, biopsies are less reliable because it is difficult to distinguish between a benign enchondroma and a low-grade chondrosarcoma.

Surgical interventions

In most situations, enchondromas do not need treatment, but require consistent monitoring and observation. However, if multiple tumours are present, treatment will be required to avoid weakening of the bone leading to fracture. In such cases, the tumour could be surgically removed by a procedure called curettage, where the tumour is scraped out of the bone. After curettage, the bone cavity may be filled with a bone graft, stabilising the bone. Periosteal and soft tissue chondromas can both be surgically removed and are quickly recognised as distinct, separate masses. Excision surgery, which involves making a skin incision and then removing the tumour entirely, is used to completely remove the tumour. Once completely removed, the tumour rarely returns.

Radiation therapy

Chemotherapy and radiation play a limited role in the treatment of chondrosarcomas.


Chondromas are benign, slow-progressing tumours that are generally painless. However, in some cases, chondromas can undergo a malignant transformation which may result in severe side effects to the bone including bone erosion, followed by fracture. Often, it is difficult to detect chondroma as patients do not display symptoms, but in some patients, chondromas may be characterised by lumps in the regions they are growing. Benign chondromas are usually left untreated unless they have the potential to develop into malignant chondrosarcomas, in which case they are surgically removed. 


  1. Tyro D, Rao GM, Kaur N, Sreenivasan A, Sharma SS. Enchondroma of Anterior Maxilla: A Rare Entity. Cureus. 2022;
  2. Gale N, Thompson LDR. Benign neoplasms of the larynx, hypopharynx, and trachea. In: Head and Neck Pathology: Second Edition. 2012.
  3. Kronenberg HM. Developmental regulation of the growth plate. Nature. 2003.
  4. Hopyan S, Gokgoz N, Poon R, Gensure RC, Yu C, Cole WG, et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet. 2002;
  5. Verdegaal SHM, Bovée JVMG, Pansuriya TC, Grimer RJ, Ozger H, Jutte PC, et al. Incidence, Predictive Factors, and Prognosis of Chondrosarcoma in Patients with Ollier Disease and Maffucci Syndrome: An International Multicenter Study of 161 Patients. Oncologist. 2011;
  6. Walden MJ, Murphey MD, Vidal JA. Incidental enchondromas of the knee. Am J Roentgenol. 2008;
  7. Bell WC, Klein MJ, Pitt MJ, Siegal GP. Molecular pathology of chondroid neoplasms: Part 1, benign lesions. Skeletal Radiology. 2006.
  8. Rajalakshmi V, Jayaraman, Anand V, Ramprasad N. Extraskeletal chondroma of the foot - A case report. J Clin Diagnostic Res. 2014;
  9. Mao BY. Extraskeletal Chondroma in the Popliteal Region: A Case Report. Chinese Med Sci J. 2015;
  10. Temsamani H, Mouhsine A, Benchafai I, Benariba F. Bilateral extraskeletal chondroma of the neck. European Annals of Otorhinolaryngology, Head and Neck Diseases. 2016.
  11. Brien EW, Mirra JM, Luck J V. Benign and malignant cartilage tumors of bone and joint: Their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. II. Juxtacortical cartilage tumors. Skeletal Radiology. 1999.
  12. Robbin MR, Murphey MD. Benign chondroid neoplasms of bone. Seminars in Musculoskeletal Radiology. 2000.
  13. Lewis MM, Kenan S, Yabut SM, Norman A, Steiner G. Periosteal chondroma. A report of ten cases and review of the literature. Clin Orthop Relat Res. 1990;
  14. Nojima T, Unni KK, McLeod RA, Pritchard DJ. Periosteal chondroma and periosteal chondrosarcoma. Am J Surg Pathol. 1985;
  15. Robinson P, White LM, Sundaram M, Kandel R, Wunder J, McDonald DJ, et al. Periosteal chondroid tumors: Radiologic evaluation with pathologic correlation. Am J Roentgenol. 2001;
  16. Fletcher CDM, Unni KK. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone Edited by. Cancer. 2002;
  17. Kosaka H, Nishio J, Matsunaga T, Aoki M, Iwasaki H, Naito M. Imaging Features of Periosteal Chondroma Manifesting as a Subcutaneous Mass in the Index Finger. Case Rep Orthop. 2014;
  18. Schwaiger K, Ensat F, Neureiter D, Wechselberger G, Hladik M. Trigger Finger Caused by Extraskeletal Chondroma. J Hand Surg Am. 2017;

Get health & wellness advice into your inbox

Your privacy is important to us. Any information you provide to us via this website may be placed by us on servers. If you do not agree to these placements, please do not provide the information.

Best Milk Alternative
[optin-monster-inline slug="yw0fgpzdy6fjeb0bbekx"]
This content is purely informational and isn’t medical guidance. It shouldn’t replace professional medical counsel. Always consult your physician regarding treatment risks and benefits. See our editorial standards for more details.

Get our health newsletter

Get daily health and wellness advice from our medical team.
Your privacy is important to us. Any information you provide to this website may be placed by us on our servers. If you do not agree do not provide the information.

Melody Deniz

Doctor of Philosophy - PhD, Regenerative Medicine | Osteoarthritis | Gene Therapy, Queen Mary University of London

Melody is a PhD student at Queen Mary University of London where she is researching gene therapy as a novel treatment for osteoarthritis. She has strong scientific and research background having several years of experience in research and development. presents all health information in line with our terms and conditions. It is essential to understand that the medical information available on our platform is not intended to substitute the relationship between a patient and their physician or doctor, as well as any medical guidance they offer. Always consult with a healthcare professional before making any decisions based on the information found on our website.
Klarity is a citizen-centric health data management platform that enables citizens to securely access, control and share their own health data. Klarity Health Library aims to provide clear and evidence-based health and wellness related informative articles. 
Klarity / Managed Self Ltd
Alum House
5 Alum Chine Road
Westbourne Bournemouth BH4 8DT
VAT Number: 362 5758 74
Company Number: 10696687

Phone Number:

 +44 20 3239 9818